AG˹ٷ

STOCK TITAN

[8-K] SouthState Corporation Reports Material Event

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

Fennec Pharmaceuticals Inc. (FENC) � Form 144 filing discloses that insider Rostislav Raykov has notified the SEC of his intent to sell up to 10,000 common shares through Morgan Stanley Smith Barney on or after 03 July 2025. At the 30 June 2025 closing price used in the filing, the aggregate market value of the proposed sale is $86,102, equivalent to roughly 0.036 % of the 27.6 million shares outstanding.

The shares stem from recently vested restricted-stock grants acquired on 16 May 2025 (7,570 sh) and 30 June 2025 (2,430 sh). The filing also details that Raykov has already disposed of 46,667 shares between 4 April and 5 June 2025 for total gross proceeds of approximately $295,398.

Rule 144 notices do not guarantee execution, but repeated insider sales within a short window can influence market sentiment. Nevertheless, the cumulative volume over the past quarter plus the planned sale (�56,667 shares) remains below 0.21 % of outstanding shares, suggesting limited dilution or supply pressure.

Fennec Pharmaceuticals Inc. (FENC) � Comunicazione Form 144 rivela che l'insider Rostislav Raykov ha notificato alla SEC la sua intenzione di vendere fino a 10.000 azioni ordinarie tramite Morgan Stanley Smith Barney a partire dal 3 luglio 2025. Al prezzo di chiusura del 30 giugno 2025 utilizzato nella comunicazione, il valore di mercato complessivo della vendita proposta è di 86.102 $, pari a circa il 0,036% delle 27,6 milioni di azioni in circolazione.

Le azioni provengono da assegnazioni di azioni vincolate recentemente maturate, acquisite il 16 maggio 2025 (7.570 azioni) e il 30 giugno 2025 (2.430 azioni). La comunicazione specifica inoltre che Raykov ha già venduto 46.667 azioni tra il 4 aprile e il 5 giugno 2025, per un ricavo lordo totale di circa 295.398 $.

Le notifiche secondo la Regola 144 non garantiscono l’effettiva esecuzione della vendita, ma vendite ripetute da parte degli insider in un breve intervallo possono influenzare il sentiment di mercato. Tuttavia, il volume cumulativo nell’ultimo trimestre più la vendita pianificata (circa 56.667 azioni) rimane inferiore al 0,21% delle azioni in circolazione, suggerendo un impatto limitato su diluizione o pressione di offerta.

Fennec Pharmaceuticals Inc. (FENC) � Presentación del Formulario 144 revela que el insider Rostislav Raykov ha notificado a la SEC su intención de vender hasta 10,000 acciones comunes a través de Morgan Stanley Smith Barney a partir del 3 de julio de 2025. Al precio de cierre del 30 de junio de 2025 usado en la presentación, el valor de mercado total de la venta propuesta es de $86,102, equivalente aproximadamente al 0.036% de las 27.6 millones de acciones en circulación.

Las acciones provienen de concesiones de acciones restringidas recientemente adquiridas, fechadas el 16 de mayo de 2025 (7,570 acciones) y el 30 de junio de 2025 (2,430 acciones). La presentación también detalla que Raykov ya ha vendido 46,667 acciones entre el 4 de abril y el 5 de junio de 2025, obteniendo ingresos brutos totales de aproximadamente $295,398.

Las notificaciones bajo la Regla 144 no garantizan la ejecución, pero ventas repetidas por parte de insiders en un corto periodo pueden influir en el sentimiento del mercado. No obstante, el volumen acumulado en el último trimestre más la venta planeada (�56,667 acciones) sigue siendo inferior al 0.21% de las acciones en circulación, lo que sugiere una dilución o presión de oferta limitada.

Fennec Pharmaceuticals Inc. (FENC) � Form 144 제출� 따르� 내부� Rostislav Raykov가 2025� 7� 3� 이후 모건 스탠� 스미� 바니� 통해 최대 10,000 보통�� 매도� 의사� SEC� 통지했습니다. 제출서류� 사용� 2025� 6� 30� 종가 기준으로, 제안� 매도� � 시장 가치는 86,102 달러�, 이는 � 2,760� � � 0.036%� 해당합니�.

� 주식들은 최근� 취득� 제한 주식으로, 2025� 5� 16� (7,570�)2025� 6� 30� (2,430�)� 각각 취득되었습니�. 제출서류에는 Raykov가 2025� 4� 4일부� 6� 5� 사이� 이미 46,667�� 매도하여 � � 295,398 달러� � 수익� 올렸다는 내용� 포함되어 있습니다.

규칙 144 통지� 매도 실행� 보장하지 않지�, 단기� � 반복되는 내부� 매도� 시장 심리� 영향� � � 있습니다. 그럼에도 불구하고, 지� 분기 누적 매도량과 계획� 매도�(� 56,667�)은 전체 발행 주식� 0.21% 미만으로, 희석 효과� 공급 압력은 제한적일 것으� 보입니다.

Fennec Pharmaceuticals Inc. (FENC) � Dépôt du formulaire 144 révèle que l’initié Rostislav Raykov a informé la SEC de son intention de vendre jusqu’� 10 000 actions ordinaires via Morgan Stanley Smith Barney à partir du 3 juillet 2025. Au cours de clôture du 30 juin 2025 utilisé pour le dépôt, la valeur totale de la vente proposée est de 86 102 $, ce qui représente environ 0,036 % des 27,6 millions d’actions en circulation.

Les actions proviennent d’attributions d’actions restreintes récemment acquises, datées du 16 mai 2025 (7 570 actions) et du 30 juin 2025 (2 430 actions). Le dépôt précise également que Raykov a déjà cédé 46 667 actions entre le 4 avril et le 5 juin 2025, pour un produit brut total d’environ 295 398 $.

Les notifications selon la règle 144 ne garantissent pas l’exécution, mais des ventes répétées d’initiés sur une courte période peuvent influencer le sentiment du marché. Néanmoins, le volume cumulé du dernier trimestre plus la vente prévue (environ 56 667 actions) reste inférieur à 0,21 % des actions en circulation, ce qui suggère une dilution ou une pression d’offre limitée.

Fennec Pharmaceuticals Inc. (FENC) � Form 144 Einreichung gibt bekannt, dass Insider Rostislav Raykov der SEC seine Absicht mitgeteilt hat, bis zu 10.000 Stammaktien über Morgan Stanley Smith Barney am oder nach dem 3. Juli 2025 zu verkaufen. Basierend auf dem Schlusskurs vom 30. Juni 2025, der in der Einreichung verwendet wurde, beträgt der Gesamtmarktwert des geplanten Verkaufs 86.102 $, was etwa 0,036 % der 27,6 Millionen ausstehenden Aktien entspricht.

Die Aktien stammen aus kürzlich fälligen Restricted-Stock-Zuweisungen vom 16. Mai 2025 (7.570 Aktien) und 30. Juni 2025 (2.430 Aktien). Die Einreichung gibt außerdem an, dass Raykov bereits zwischen dem 4. April und 5. Juni 2025 46.667 Aktien veräußert hat und dabei Bruttoerlöse von etwa 295.398 $ erzielte.

Rule 144-Mitteilungen garantieren keine Ausführung, aber wiederholte Insiderverkäufe in kurzer Zeit können die Marktstimmung beeinflussen. Dennoch bleibt das kumulierte Volumen im letzten Quartal zuzüglich des geplanten Verkaufs (ca. 56.667 Aktien) unter 0,21 % der ausstehenden Aktien, was auf eine begrenzte Verwässerung oder Angebotsdruck hindeutet.

Positive
  • None.
Negative
  • Continued insider selling by the same executive within a three-month span may raise minor sentiment concerns despite small relative volume.

Insights

TL;DR � Small insider sale; signal slightly negative but immaterial to float.

The proposed 10 k-share sale represents a de-minimis 0.04 % of shares outstanding. While continued selling by the same insider may be read as waning confidence, the notional value is modest ($86k) and follows recent option/RSU vesting. From a liquidity standpoint, the NASDAQ daily volume averages far above this level, so price impact should be minimal. I view the disclosure as neutral-to-slightly negative for sentiment, with no change to fundamentals.

TL;DR � Patterned insider disposals warrant monitoring for governance optics.

Raykov has filed multiple Form 144s and executed sales over three consecutive months, signalling a structured liquidation program. Although Rule 144 compliance and 10b5-1 safeguards are noted, investors often scrutinise repeat sales by senior officers for alignment concerns. Yet, aggregate disposals remain far below thresholds that typically trigger governance red flags. I deem the filing not materially impactful but recommend tracking future filings to confirm whether the pattern escalates.

Fennec Pharmaceuticals Inc. (FENC) � Comunicazione Form 144 rivela che l'insider Rostislav Raykov ha notificato alla SEC la sua intenzione di vendere fino a 10.000 azioni ordinarie tramite Morgan Stanley Smith Barney a partire dal 3 luglio 2025. Al prezzo di chiusura del 30 giugno 2025 utilizzato nella comunicazione, il valore di mercato complessivo della vendita proposta è di 86.102 $, pari a circa il 0,036% delle 27,6 milioni di azioni in circolazione.

Le azioni provengono da assegnazioni di azioni vincolate recentemente maturate, acquisite il 16 maggio 2025 (7.570 azioni) e il 30 giugno 2025 (2.430 azioni). La comunicazione specifica inoltre che Raykov ha già venduto 46.667 azioni tra il 4 aprile e il 5 giugno 2025, per un ricavo lordo totale di circa 295.398 $.

Le notifiche secondo la Regola 144 non garantiscono l’effettiva esecuzione della vendita, ma vendite ripetute da parte degli insider in un breve intervallo possono influenzare il sentiment di mercato. Tuttavia, il volume cumulativo nell’ultimo trimestre più la vendita pianificata (circa 56.667 azioni) rimane inferiore al 0,21% delle azioni in circolazione, suggerendo un impatto limitato su diluizione o pressione di offerta.

Fennec Pharmaceuticals Inc. (FENC) � Presentación del Formulario 144 revela que el insider Rostislav Raykov ha notificado a la SEC su intención de vender hasta 10,000 acciones comunes a través de Morgan Stanley Smith Barney a partir del 3 de julio de 2025. Al precio de cierre del 30 de junio de 2025 usado en la presentación, el valor de mercado total de la venta propuesta es de $86,102, equivalente aproximadamente al 0.036% de las 27.6 millones de acciones en circulación.

Las acciones provienen de concesiones de acciones restringidas recientemente adquiridas, fechadas el 16 de mayo de 2025 (7,570 acciones) y el 30 de junio de 2025 (2,430 acciones). La presentación también detalla que Raykov ya ha vendido 46,667 acciones entre el 4 de abril y el 5 de junio de 2025, obteniendo ingresos brutos totales de aproximadamente $295,398.

Las notificaciones bajo la Regla 144 no garantizan la ejecución, pero ventas repetidas por parte de insiders en un corto periodo pueden influir en el sentimiento del mercado. No obstante, el volumen acumulado en el último trimestre más la venta planeada (�56,667 acciones) sigue siendo inferior al 0.21% de las acciones en circulación, lo que sugiere una dilución o presión de oferta limitada.

Fennec Pharmaceuticals Inc. (FENC) � Form 144 제출� 따르� 내부� Rostislav Raykov가 2025� 7� 3� 이후 모건 스탠� 스미� 바니� 통해 최대 10,000 보통�� 매도� 의사� SEC� 통지했습니다. 제출서류� 사용� 2025� 6� 30� 종가 기준으로, 제안� 매도� � 시장 가치는 86,102 달러�, 이는 � 2,760� � � 0.036%� 해당합니�.

� 주식들은 최근� 취득� 제한 주식으로, 2025� 5� 16� (7,570�)2025� 6� 30� (2,430�)� 각각 취득되었습니�. 제출서류에는 Raykov가 2025� 4� 4일부� 6� 5� 사이� 이미 46,667�� 매도하여 � � 295,398 달러� � 수익� 올렸다는 내용� 포함되어 있습니다.

규칙 144 통지� 매도 실행� 보장하지 않지�, 단기� � 반복되는 내부� 매도� 시장 심리� 영향� � � 있습니다. 그럼에도 불구하고, 지� 분기 누적 매도량과 계획� 매도�(� 56,667�)은 전체 발행 주식� 0.21% 미만으로, 희석 효과� 공급 압력은 제한적일 것으� 보입니다.

Fennec Pharmaceuticals Inc. (FENC) � Dépôt du formulaire 144 révèle que l’initié Rostislav Raykov a informé la SEC de son intention de vendre jusqu’� 10 000 actions ordinaires via Morgan Stanley Smith Barney à partir du 3 juillet 2025. Au cours de clôture du 30 juin 2025 utilisé pour le dépôt, la valeur totale de la vente proposée est de 86 102 $, ce qui représente environ 0,036 % des 27,6 millions d’actions en circulation.

Les actions proviennent d’attributions d’actions restreintes récemment acquises, datées du 16 mai 2025 (7 570 actions) et du 30 juin 2025 (2 430 actions). Le dépôt précise également que Raykov a déjà cédé 46 667 actions entre le 4 avril et le 5 juin 2025, pour un produit brut total d’environ 295 398 $.

Les notifications selon la règle 144 ne garantissent pas l’exécution, mais des ventes répétées d’initiés sur une courte période peuvent influencer le sentiment du marché. Néanmoins, le volume cumulé du dernier trimestre plus la vente prévue (environ 56 667 actions) reste inférieur à 0,21 % des actions en circulation, ce qui suggère une dilution ou une pression d’offre limitée.

Fennec Pharmaceuticals Inc. (FENC) � Form 144 Einreichung gibt bekannt, dass Insider Rostislav Raykov der SEC seine Absicht mitgeteilt hat, bis zu 10.000 Stammaktien über Morgan Stanley Smith Barney am oder nach dem 3. Juli 2025 zu verkaufen. Basierend auf dem Schlusskurs vom 30. Juni 2025, der in der Einreichung verwendet wurde, beträgt der Gesamtmarktwert des geplanten Verkaufs 86.102 $, was etwa 0,036 % der 27,6 Millionen ausstehenden Aktien entspricht.

Die Aktien stammen aus kürzlich fälligen Restricted-Stock-Zuweisungen vom 16. Mai 2025 (7.570 Aktien) und 30. Juni 2025 (2.430 Aktien). Die Einreichung gibt außerdem an, dass Raykov bereits zwischen dem 4. April und 5. Juni 2025 46.667 Aktien veräußert hat und dabei Bruttoerlöse von etwa 295.398 $ erzielte.

Rule 144-Mitteilungen garantieren keine Ausführung, aber wiederholte Insiderverkäufe in kurzer Zeit können die Marktstimmung beeinflussen. Dennoch bleibt das kumulierte Volumen im letzten Quartal zuzüglich des geplanten Verkaufs (ca. 56.667 Aktien) unter 0,21 % der ausstehenden Aktien, was auf eine begrenzte Verwässerung oder Angebotsdruck hindeutet.

0000764038false00007640382025-07-032025-07-03
UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON, D.C. 20549FORM 8-KCURRENT REPORTPursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934Date of Report (Date of earliest event reported): July 3, 2025GraphicSOUTHSTATE CORPORATION (Exact name of registrant as specified in its charter)
South Carolina(State or Other Jurisdiction ofIncorporation)001-12669(Commission File Number)57-0799315(IRS EmployerIdentification No.)
1101 First Street South, Suite 202Winter Haven, FL(Address of principal executive offices)33880(Zip Code)
(863) 293-4710(Registrant’s telephone number, including area code)Not Applicable(Former name or former address, if changed since last report)Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common stock, par value $2.50 per shareSSBThe New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).Emerging growth company       If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  

4
Item 7.01Regulation FD Disclosures.
SouthState Corporation to announce quarterly earnings results on Thursday, July 24, 2025Winter Haven, FL. – July 3, 2025 – SouthState Corporation (NYSE: SSB) (“SouthState”) announced today that it will release second quarter 2025 earnings results on Thursday, July 24, 2025, after the market closes. Upon release, investors may access a copy of SouthState’s earnings results at the Company’s website at www.SouthStateBank.com under Investor Relations, News, News & Market Data section. SouthState will host a conference call on Friday, July 25, 2025 at 9:00 a.m. (ET) to discuss its second quarter 2025 results. Investors may call in (toll free) by dialing (888) 350-3899 within the US and (646) 960-0343 for all other locations (host: Will Matthews, CFO). The numbers for international participants are listed at https://events.q4irportal.com/custom/access/2324/. The conference ID number is 4200408. Participants may also pre-register for the conference by navigating to https://events.q4inc.com/attendee/102549480. Access detail will be provided via email upon completion of registration. Alternatively, individuals may listen to the live webcast of the presentation by visiting the link at SouthState’s website at www.SouthStateBank.com. An audio replay of the live webcast is expected to be available by the evening of Friday, July 25, 2025 through the Investor Relations section of www.SouthStateBank.com.In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Item 9.01Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No.Description of Exhibit
99.1Press release dated July 3, 2025
104Cover Page Interactive Data File (embedded within the Inline XBRL document)
2
SIGNATURESPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
SOUTHSTATE CORPORATION
(Registrant)
By:/s/ William E. Matthews, V
William E. Matthews, V
Senior Executive Vice President and
Chief Financial Officer
Dated: July 3, 2025
3

FAQ

How many FENC shares is the insider planning to sell under this Form 144?

Up to 10,000 common shares are slated for sale.

What is the aggregate market value of the proposed FENC share sale?

The filing lists an aggregate value of approximately $86,102.

When is the anticipated sale date for the FENC shares?

The approximate sale date disclosed is 03 July 2025.

How many FENC shares has the insider already sold in the past three months?

The insider reported selling 46,667 shares between 4 April and 5 June 2025.

What percentage of Fennec Pharmaceuticals� shares outstanding does the planned sale represent?

Roughly 0.036 % of the 27.6 million shares outstanding.

Which brokerage firm is handling the planned sale of FENC shares?

Morgan Stanley Smith Barney LLC is listed as the executing broker.
Southstate Corporation

NYSE:SSB

SSB Rankings

SSB Latest News

SSB Stock Data

9.33B
100.20M
1.2%
70.25%
3.57%
Banks - Regional
State Commercial Banks
United States
WINTER HAVEN